Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
I'm PortAI, I can summarize articles.
Fate Therapeutics Inc. reported a Q3 net loss of $32.25 million, down from $47.68 million last year, amid restructuring efforts to streamline operations and extend its cash runway. Collaboration revenue fell to $1.74 million from $3.07 million. Despite losses, the company invested $25.84 million in R&D and focuses on strategic partnerships, notably with Ono Pharmaceutical, to advance its iPSC platform and clinical programs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments